MONIA MARCHETTI - Academia.edu (original) (raw)
Papers by MONIA MARCHETTI
Journal of Clinical Medicine, 2022
Background: The treatment of endocrinopathies in haemoglobinopathies is a continually expanding r... more Background: The treatment of endocrinopathies in haemoglobinopathies is a continually expanding research area; therefore, recommendations supporting the appropriateness of treatments are a pressing need for the medical community. Methods: The Management Committee of SITE selected and gathered a multidisciplinary and multi-professional team, including experts in haemoglobinopathies and experts in endocrinopathies, who have been flanked by experts with methodological and organizational expertise, in order to formulate recommendations based on the available scientific evidence integrated by personal clinical experience. The project followed the systematic approach for the production of clinical practice guidelines according to the methodology suggested by the National Center for Clinical Excellence, Quality and Safety of Care (CNEC). Results: Out of 14 topics, 100 clinical questions were addressed, and 206 recommendations were elaborated on. The strength of recommendations, panel agree...
HemaSphere, 2021
Zynteglo Autologous CD34+ cells encoding β A-T87Q-globin gene On 28 March 2019, the Committee for... more Zynteglo Autologous CD34+ cells encoding β A-T87Q-globin gene On 28 March 2019, the Committee for Medicinal Products for Human Use (CHMP) on the basis of the draft Committee for Advanced Therapies opinion, adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Zynteglo, intended for the treatment of transfusion-dependent β-thalassaemia (TDT). Zynteglo EMA/CHMP/166977/2019 Page 2/2 characteristics (SmPC), which will be published in the European public assessment report (EPAR) and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.
Hematological Oncology, Mar 26, 2021
Journal of Clinical Medicine, Mar 28, 2022
This article is an open access article distributed under the terms and conditions of the Creative... more This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY
Frontiers in Immunology
BackgroundThe outcome of COVID-19 in allogeneic hematopoietic stem cell transplantation (HSCT) re... more BackgroundThe outcome of COVID-19 in allogeneic hematopoietic stem cell transplantation (HSCT) recipients is almost uniformely considered poor. The aim of present study was to retrospectively analyse the outcome and risk factors for mortality in a large series of patients who developed COVID-19 infection after an allogeneic HSCT.MethodsThis multicenter retrospective study promoted by the European Hematology Association – Infections in Hematology Study Working Group, included 326 adult HSCT patients who had COVID-19 between January 2020 and March 2022.ResultsThe median time from HSCT to the diagnosis of COVID-19 was 268 days (IQR 86-713; range 0-185 days). COVID-19 severity was mild in 21% of the patients, severe in 39% and critical in 16% of the patients. In multivariable analysis factors associated with a higher risk of mortality were, age above 50 years, presence of 3 or more comorbidities, active hematologic disease at time of COVID-19 infection, development of COVID-19 within 12...
QJM, 2001
Carriers of a double thrombophilic mutation (factor V Leiden and prothrombin G20210A) are at high... more Carriers of a double thrombophilic mutation (factor V Leiden and prothrombin G20210A) are at high risk of a recurrent venous thromboembolism (VTE), and may benefit from a longer course of secondary prophylaxis. We examined the costs and health benefits of screening for both the mutations, provided that double heterozygotes undergo 2 years of anticoagulation as compared to the standard 6 months. We thus pooled the available evidence and calculated that the OR for recurrence in double heterozygotes was 5.9 (95% CI 2.65±13.20). A Markov model tracked patients' health lifelong, and calculated that prolonged prophylaxis saved 26 quality-adjusted days of life and 410perdoubleheterozygotetreated.Screeningallthepatientswithvenousthromboembolismthusprovidedoneadditionaldayoflifeatthecostof13624410 per double heterozygote treated. Screening all the patients with venous thromboembolism thus provided one additional day of life at the cost of 13 624 410perdoubleheterozygotetreated.Screeningallthepatientswithvenousthromboembolismthusprovidedoneadditionaldayoflifeatthecostof13624/QALY (95% CI 12 965±22 889). Screening was not cost-effective in those cohorts with a low prevalence of the mutations, a high bleeding risk or in those where prophylaxis prevented-65% of recurrences. Screening for factor V Leiden and prothrombin G20210A, with prolonged prophylaxis of double carriers, is cost-effective in most patients with VTE. Methods Meta-analysis English-written articles dealing with recurrent VTE were obtained from a computerized search of Medline 1966±2000 (July). In the MESH field, the
Journal of Clinical Medicine, Apr 7, 2022
This article is an open access article distributed under the terms and conditions of the Creative... more This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY
MGA (11%), POT1 (11%), and BIRC3 (10%) were reported in ≥10% of cases. The median follow-up of pa... more MGA (11%), POT1 (11%), and BIRC3 (10%) were reported in ≥10% of cases. The median follow-up of patients was 2.8 years. Median time on ibrutinib was 29 months. Discontinuation of ibrutinib due to any reason except progressive disease (PD) was reported in 21% of patients and their median time on ibrutinib was 17 months. Median time to discontinuation due to any reason except PD was 16 months. At least 1 interruption was reported in 31% of patients, and 6% interrupted treatment >1 time. The median consecutive days of interruption was 28 and the median total days of interruption was 38. Dose reduction was required by 25% of patients, including 5% who reduced to 140 mg/d. Median dose intensity (proportion of administered vs planned doses of ibrutinib 420 mg/d) was 93.4%. Three-years PFS of the per protocol cohort was 80.3% (CI 69.9-92.2). Early discontinuation due to any reason except PD, treatment interruption, regardless of duration (≥1, ≥8, ≥14 and ≥21 consecutive days), and dose reduction had no impact on PFS. By recursive partitioning, PFS stratification based on the best cutoff for dose intensity did not show a negative outcome, indicating no compounded effect of both dose reduction and interruption. Conclusions: Ibrutinib treatment modifications seem not to have major impact on PFS in patients with high-risk CLL. The impact of ibrutinib dose intensity during the first months of therapy on PFS, and the impact of ibrutinib tolerability on time to next treatment will be explored in this dataset.
Blood, 2020
Fixed-duration treatment with venetoclax (Ven), a highly selective Bcl-2 inhibitor combined with ... more Fixed-duration treatment with venetoclax (Ven), a highly selective Bcl-2 inhibitor combined with an anti-CD20 monoclonal antibody, showed high efficacy inducing high rates of deep responses with undetectable minimal residual disease (uMRD) in patients with previously treated and untreated chronic lymphocytic leukemia (CLL). The efficacy and safety of the Ven and rituximab (VenR) combination have been investigated in a multicenter, prospective study of the GIMEMA group that included young patients with previously untreated CLL (LLC 1518, VERITAS, NCT03455517). The primary endpoint of this study was the CR rate assessed according to the iwCLL criteria. Inclusion criteria were: treatment requirement per iwCLL criteria, age ≤65 years, cumulative Illness rating scale score ≤6, creatinine clearance ≥30 mL/min, and an unfavorable biologic profile with IGHV unmutated and or TP53 disruption. Treatment consisted of the Ven dose ramp-up (from 20 to 400 mg daily, during 5-weeks) followed by Ven...
Annals of Hematology, 2020
COVID-19 pandemia is a major health emergency causing hundreds of deaths worldwide. The high repo... more COVID-19 pandemia is a major health emergency causing hundreds of deaths worldwide. The high reported morbidity has been related to hypoxia and inflammation leading to endothelial dysfunction and aberrant coagulation in small and large vessels. This review addresses some of the pathways leading to endothelial derangement, such as complement, HIF-1α, and ABL tyrosine kinases. This review also highlights potential targets for prevention and therapy of COVID-19-related organ damage and discusses the role of marketed drugs, such as eculizumab and imatinib, as suitable candidates for clinical trials.
Haematologica, 2006
The Italian Society of Hematology (SIE) and two affiliate societies (SIES and GITMO) commissioned... more The Italian Society of Hematology (SIE) and two affiliate societies (SIES and GITMO) commissioned a project to develop clinical practice guidelines for the treatment of nodal diffuse large B-cell non Hodgkin lymphomas (DLBCL). Key questions clinically relevant to the management of patients with nodal DLBCL were formulated by an Advisory Committee (AC) and approved by an Expert Panel (EP) composed of eight senior hematologists. After a comprehensive and systematic literature review, the EP formulated therapy recommendations and graded them according to the supporting evidence. An explicit approach to consensus methodologies was used for evidence interpretation and for producing recommendations in the absence of strong evidence. The EP formulated recommendations on which first-line therapy to choose in patients with nodal DLBCL. Patients of all ages, with stage I-II disease and no adverse prognostic factors should receive abbreviated chemotherapy with an anthracycline-containing regim...
Blood Cancer Journal
Understanding antibody-based SARS-CoV-2 immunity in hematologic malignancy (HM) patients followin... more Understanding antibody-based SARS-CoV-2 immunity in hematologic malignancy (HM) patients following infection is crucial to inform vaccination strategies for this highly vulnerable population. This cross-sectional study documents the anti-SARS-CoV-2 humoral response and serum neutralizing activity in 189 HM patients recovering from a PCR-confirmed infection. The overall seroconversion rate was 85.7%, with the lowest values in patients with lymphoid malignancies or undergoing chemotherapy. Therapy-naive patients in the “watch and wait” status were more likely to seroconvert and display increased anti-s IgG titers. Enhanced serum neutralizing activity was observed in the following SARS-CoV-2-infected HM patient groups: (i) males; (ii) severe COVID-19; and (iii) “watch and wait” or “complete/partial response”. The geometric mean (GeoMean) ID50 neutralization titers in patients analyzed before or after 6 months post-infection were 299.1 and 306.3, respectively, indicating that >50% of...
Non-Hodgkin’s lymphomas (NHL)account for 4 % of all cancers:1 ofthese, about 40 % are indolent NH... more Non-Hodgkin’s lymphomas (NHL)account for 4 % of all cancers:1 ofthese, about 40 % are indolent NHL, which are characterized by a long disease course.2,3 The median survival of 8-9 years4,5 has improved slightly in the last 20 years,6,7 but lymphoma continues to be the principal cause of death in these patients. New strategies have recently been introduced into the therapy of indo-lent NHL and the integration of older and more recent research results may lead to conflicting conclusions resulting in large variation in clinical practice. In order to offer the best available treat-ments to patients, since 2001 the Italian Society of Hematology (SIE) has been sup-porting the development of clinical prac-tice guidelines in the therapy of selected hematologic diseases. In 2002, the Italian
The annual incidence of large B-celllymphoma (DLBCL) is 2-8 cases per100,000 inhabitants per year... more The annual incidence of large B-celllymphoma (DLBCL) is 2-8 cases per100,000 inhabitants per year.1 This disease accounts for 20 to 40 % of cases of non-Hodgkin’s lymphoma (NHL),1-3 and the median overall survival (OS) of patients with DLBCL is shorter than 5 years.4 Several therapeutic innovations have been recently introduced, and subjective integration of older and new pieces of evidence may lead to conflicting conclusions and a large varia-tion in clinical practice. In order to select the best available treatments, avoiding inappro-priate ones, the Italian Society of Hema-tology (SIE), the Italian Society of Experimental Hematology (SIES) and the
Clinical Lymphoma Myeloma and Leukemia
S214 CLL-101 Regulation of HIF-1 a in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its P... more S214 CLL-101 Regulation of HIF-1 a in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role as a Therapeutic Target Candida Vitale ,1,y Valentina Griggio,1,y Maria Todaro, Chiara Riganti, Joanna Kopecka, Chiara Salvetti, Riccardo Bomben, Michele Dal Bo, Davide Rossi, Gabriele Pozzato, Monia Marchetti, Paola Omedè, Lisa Bonello, Ahad Ahmed Kodipad, Luca Laurenti, Giovanni Del Poeta, Francesca Romana Mauro, Rosa Bernardi, Valter Gattei, Gianluca Gaidano, Robin Foà, Massimo Massaia, Mario Boccadoro, Marta Coscia Division of Hematology, University of Torino, A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy; Department of Oncology, University of Torino, Torino, Italy; Clinical and Experimental OncoHematology Unit, CRO Aviano National Cancer Institute, Aviano, Italy; Department of Hematology, Oncology Institute of Southern Switzerland and Institute of Oncology Research, Bellinzona, Switzerland; Department of Internal Medicine and Hematology, Maggiore General Hospital, University of Trieste, Trieste, Italy; Hematology Day Service, Oncology SOC, Hospital Cardinal Massaia, Asti, Italy; Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy; Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy; Department of Hematology, Catholic University of Sacred Heart, Roma, Italy; Division of Hematology, S. Eugenio Hospital and University of Tor Vergata, Roma, Italy; Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University, Roma, Italy; Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milano, Italy; Ematology Unit, ASO Santa Croce e Carle, Cuneo, Italy
Blood
Introduction and Aim Till today, the only curative and most widely used therapy for β-thalassemia... more Introduction and Aim Till today, the only curative and most widely used therapy for β-thalassemia (β-TDT) is allogeneic HSCT: the European Society for Bone Marrow Transplantation Hemoglobinopathy Registry reported over 90% overall survival in under-14 patients transplanted from an HLA identical family donor. However, with the new therapeutic scenario opened up by Gene Therapy (GT), it has become essential to identify and prioritize patient profiles for which GT could be applied. The "Pesaro Patients Risk Classification" showed the importance of risk stratification in order to achieve the best results. The Italian Scientific Society for Thalassemias and Hemoglobinopathies (SITE) closely involved in the cure and overall approach to these pathologies, decided to carry out this project of analysis and assessment to establish the possible inclusion and exclusion criteria for access to GT of patients with β-TDT and to collect the outcomes. The aim of this study is to identify wh...
Clinical Lymphoma Myeloma and Leukemia
Journal of Clinical Medicine, 2022
Background: The treatment of endocrinopathies in haemoglobinopathies is a continually expanding r... more Background: The treatment of endocrinopathies in haemoglobinopathies is a continually expanding research area; therefore, recommendations supporting the appropriateness of treatments are a pressing need for the medical community. Methods: The Management Committee of SITE selected and gathered a multidisciplinary and multi-professional team, including experts in haemoglobinopathies and experts in endocrinopathies, who have been flanked by experts with methodological and organizational expertise, in order to formulate recommendations based on the available scientific evidence integrated by personal clinical experience. The project followed the systematic approach for the production of clinical practice guidelines according to the methodology suggested by the National Center for Clinical Excellence, Quality and Safety of Care (CNEC). Results: Out of 14 topics, 100 clinical questions were addressed, and 206 recommendations were elaborated on. The strength of recommendations, panel agree...
HemaSphere, 2021
Zynteglo Autologous CD34+ cells encoding β A-T87Q-globin gene On 28 March 2019, the Committee for... more Zynteglo Autologous CD34+ cells encoding β A-T87Q-globin gene On 28 March 2019, the Committee for Medicinal Products for Human Use (CHMP) on the basis of the draft Committee for Advanced Therapies opinion, adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Zynteglo, intended for the treatment of transfusion-dependent β-thalassaemia (TDT). Zynteglo EMA/CHMP/166977/2019 Page 2/2 characteristics (SmPC), which will be published in the European public assessment report (EPAR) and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.
Hematological Oncology, Mar 26, 2021
Journal of Clinical Medicine, Mar 28, 2022
This article is an open access article distributed under the terms and conditions of the Creative... more This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY
Frontiers in Immunology
BackgroundThe outcome of COVID-19 in allogeneic hematopoietic stem cell transplantation (HSCT) re... more BackgroundThe outcome of COVID-19 in allogeneic hematopoietic stem cell transplantation (HSCT) recipients is almost uniformely considered poor. The aim of present study was to retrospectively analyse the outcome and risk factors for mortality in a large series of patients who developed COVID-19 infection after an allogeneic HSCT.MethodsThis multicenter retrospective study promoted by the European Hematology Association – Infections in Hematology Study Working Group, included 326 adult HSCT patients who had COVID-19 between January 2020 and March 2022.ResultsThe median time from HSCT to the diagnosis of COVID-19 was 268 days (IQR 86-713; range 0-185 days). COVID-19 severity was mild in 21% of the patients, severe in 39% and critical in 16% of the patients. In multivariable analysis factors associated with a higher risk of mortality were, age above 50 years, presence of 3 or more comorbidities, active hematologic disease at time of COVID-19 infection, development of COVID-19 within 12...
QJM, 2001
Carriers of a double thrombophilic mutation (factor V Leiden and prothrombin G20210A) are at high... more Carriers of a double thrombophilic mutation (factor V Leiden and prothrombin G20210A) are at high risk of a recurrent venous thromboembolism (VTE), and may benefit from a longer course of secondary prophylaxis. We examined the costs and health benefits of screening for both the mutations, provided that double heterozygotes undergo 2 years of anticoagulation as compared to the standard 6 months. We thus pooled the available evidence and calculated that the OR for recurrence in double heterozygotes was 5.9 (95% CI 2.65±13.20). A Markov model tracked patients' health lifelong, and calculated that prolonged prophylaxis saved 26 quality-adjusted days of life and 410perdoubleheterozygotetreated.Screeningallthepatientswithvenousthromboembolismthusprovidedoneadditionaldayoflifeatthecostof13624410 per double heterozygote treated. Screening all the patients with venous thromboembolism thus provided one additional day of life at the cost of 13 624 410perdoubleheterozygotetreated.Screeningallthepatientswithvenousthromboembolismthusprovidedoneadditionaldayoflifeatthecostof13624/QALY (95% CI 12 965±22 889). Screening was not cost-effective in those cohorts with a low prevalence of the mutations, a high bleeding risk or in those where prophylaxis prevented-65% of recurrences. Screening for factor V Leiden and prothrombin G20210A, with prolonged prophylaxis of double carriers, is cost-effective in most patients with VTE. Methods Meta-analysis English-written articles dealing with recurrent VTE were obtained from a computerized search of Medline 1966±2000 (July). In the MESH field, the
Journal of Clinical Medicine, Apr 7, 2022
This article is an open access article distributed under the terms and conditions of the Creative... more This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY
MGA (11%), POT1 (11%), and BIRC3 (10%) were reported in ≥10% of cases. The median follow-up of pa... more MGA (11%), POT1 (11%), and BIRC3 (10%) were reported in ≥10% of cases. The median follow-up of patients was 2.8 years. Median time on ibrutinib was 29 months. Discontinuation of ibrutinib due to any reason except progressive disease (PD) was reported in 21% of patients and their median time on ibrutinib was 17 months. Median time to discontinuation due to any reason except PD was 16 months. At least 1 interruption was reported in 31% of patients, and 6% interrupted treatment >1 time. The median consecutive days of interruption was 28 and the median total days of interruption was 38. Dose reduction was required by 25% of patients, including 5% who reduced to 140 mg/d. Median dose intensity (proportion of administered vs planned doses of ibrutinib 420 mg/d) was 93.4%. Three-years PFS of the per protocol cohort was 80.3% (CI 69.9-92.2). Early discontinuation due to any reason except PD, treatment interruption, regardless of duration (≥1, ≥8, ≥14 and ≥21 consecutive days), and dose reduction had no impact on PFS. By recursive partitioning, PFS stratification based on the best cutoff for dose intensity did not show a negative outcome, indicating no compounded effect of both dose reduction and interruption. Conclusions: Ibrutinib treatment modifications seem not to have major impact on PFS in patients with high-risk CLL. The impact of ibrutinib dose intensity during the first months of therapy on PFS, and the impact of ibrutinib tolerability on time to next treatment will be explored in this dataset.
Blood, 2020
Fixed-duration treatment with venetoclax (Ven), a highly selective Bcl-2 inhibitor combined with ... more Fixed-duration treatment with venetoclax (Ven), a highly selective Bcl-2 inhibitor combined with an anti-CD20 monoclonal antibody, showed high efficacy inducing high rates of deep responses with undetectable minimal residual disease (uMRD) in patients with previously treated and untreated chronic lymphocytic leukemia (CLL). The efficacy and safety of the Ven and rituximab (VenR) combination have been investigated in a multicenter, prospective study of the GIMEMA group that included young patients with previously untreated CLL (LLC 1518, VERITAS, NCT03455517). The primary endpoint of this study was the CR rate assessed according to the iwCLL criteria. Inclusion criteria were: treatment requirement per iwCLL criteria, age ≤65 years, cumulative Illness rating scale score ≤6, creatinine clearance ≥30 mL/min, and an unfavorable biologic profile with IGHV unmutated and or TP53 disruption. Treatment consisted of the Ven dose ramp-up (from 20 to 400 mg daily, during 5-weeks) followed by Ven...
Annals of Hematology, 2020
COVID-19 pandemia is a major health emergency causing hundreds of deaths worldwide. The high repo... more COVID-19 pandemia is a major health emergency causing hundreds of deaths worldwide. The high reported morbidity has been related to hypoxia and inflammation leading to endothelial dysfunction and aberrant coagulation in small and large vessels. This review addresses some of the pathways leading to endothelial derangement, such as complement, HIF-1α, and ABL tyrosine kinases. This review also highlights potential targets for prevention and therapy of COVID-19-related organ damage and discusses the role of marketed drugs, such as eculizumab and imatinib, as suitable candidates for clinical trials.
Haematologica, 2006
The Italian Society of Hematology (SIE) and two affiliate societies (SIES and GITMO) commissioned... more The Italian Society of Hematology (SIE) and two affiliate societies (SIES and GITMO) commissioned a project to develop clinical practice guidelines for the treatment of nodal diffuse large B-cell non Hodgkin lymphomas (DLBCL). Key questions clinically relevant to the management of patients with nodal DLBCL were formulated by an Advisory Committee (AC) and approved by an Expert Panel (EP) composed of eight senior hematologists. After a comprehensive and systematic literature review, the EP formulated therapy recommendations and graded them according to the supporting evidence. An explicit approach to consensus methodologies was used for evidence interpretation and for producing recommendations in the absence of strong evidence. The EP formulated recommendations on which first-line therapy to choose in patients with nodal DLBCL. Patients of all ages, with stage I-II disease and no adverse prognostic factors should receive abbreviated chemotherapy with an anthracycline-containing regim...
Blood Cancer Journal
Understanding antibody-based SARS-CoV-2 immunity in hematologic malignancy (HM) patients followin... more Understanding antibody-based SARS-CoV-2 immunity in hematologic malignancy (HM) patients following infection is crucial to inform vaccination strategies for this highly vulnerable population. This cross-sectional study documents the anti-SARS-CoV-2 humoral response and serum neutralizing activity in 189 HM patients recovering from a PCR-confirmed infection. The overall seroconversion rate was 85.7%, with the lowest values in patients with lymphoid malignancies or undergoing chemotherapy. Therapy-naive patients in the “watch and wait” status were more likely to seroconvert and display increased anti-s IgG titers. Enhanced serum neutralizing activity was observed in the following SARS-CoV-2-infected HM patient groups: (i) males; (ii) severe COVID-19; and (iii) “watch and wait” or “complete/partial response”. The geometric mean (GeoMean) ID50 neutralization titers in patients analyzed before or after 6 months post-infection were 299.1 and 306.3, respectively, indicating that >50% of...
Non-Hodgkin’s lymphomas (NHL)account for 4 % of all cancers:1 ofthese, about 40 % are indolent NH... more Non-Hodgkin’s lymphomas (NHL)account for 4 % of all cancers:1 ofthese, about 40 % are indolent NHL, which are characterized by a long disease course.2,3 The median survival of 8-9 years4,5 has improved slightly in the last 20 years,6,7 but lymphoma continues to be the principal cause of death in these patients. New strategies have recently been introduced into the therapy of indo-lent NHL and the integration of older and more recent research results may lead to conflicting conclusions resulting in large variation in clinical practice. In order to offer the best available treat-ments to patients, since 2001 the Italian Society of Hematology (SIE) has been sup-porting the development of clinical prac-tice guidelines in the therapy of selected hematologic diseases. In 2002, the Italian
The annual incidence of large B-celllymphoma (DLBCL) is 2-8 cases per100,000 inhabitants per year... more The annual incidence of large B-celllymphoma (DLBCL) is 2-8 cases per100,000 inhabitants per year.1 This disease accounts for 20 to 40 % of cases of non-Hodgkin’s lymphoma (NHL),1-3 and the median overall survival (OS) of patients with DLBCL is shorter than 5 years.4 Several therapeutic innovations have been recently introduced, and subjective integration of older and new pieces of evidence may lead to conflicting conclusions and a large varia-tion in clinical practice. In order to select the best available treatments, avoiding inappro-priate ones, the Italian Society of Hema-tology (SIE), the Italian Society of Experimental Hematology (SIES) and the
Clinical Lymphoma Myeloma and Leukemia
S214 CLL-101 Regulation of HIF-1 a in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its P... more S214 CLL-101 Regulation of HIF-1 a in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role as a Therapeutic Target Candida Vitale ,1,y Valentina Griggio,1,y Maria Todaro, Chiara Riganti, Joanna Kopecka, Chiara Salvetti, Riccardo Bomben, Michele Dal Bo, Davide Rossi, Gabriele Pozzato, Monia Marchetti, Paola Omedè, Lisa Bonello, Ahad Ahmed Kodipad, Luca Laurenti, Giovanni Del Poeta, Francesca Romana Mauro, Rosa Bernardi, Valter Gattei, Gianluca Gaidano, Robin Foà, Massimo Massaia, Mario Boccadoro, Marta Coscia Division of Hematology, University of Torino, A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy; Department of Oncology, University of Torino, Torino, Italy; Clinical and Experimental OncoHematology Unit, CRO Aviano National Cancer Institute, Aviano, Italy; Department of Hematology, Oncology Institute of Southern Switzerland and Institute of Oncology Research, Bellinzona, Switzerland; Department of Internal Medicine and Hematology, Maggiore General Hospital, University of Trieste, Trieste, Italy; Hematology Day Service, Oncology SOC, Hospital Cardinal Massaia, Asti, Italy; Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy; Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy; Department of Hematology, Catholic University of Sacred Heart, Roma, Italy; Division of Hematology, S. Eugenio Hospital and University of Tor Vergata, Roma, Italy; Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University, Roma, Italy; Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milano, Italy; Ematology Unit, ASO Santa Croce e Carle, Cuneo, Italy
Blood
Introduction and Aim Till today, the only curative and most widely used therapy for β-thalassemia... more Introduction and Aim Till today, the only curative and most widely used therapy for β-thalassemia (β-TDT) is allogeneic HSCT: the European Society for Bone Marrow Transplantation Hemoglobinopathy Registry reported over 90% overall survival in under-14 patients transplanted from an HLA identical family donor. However, with the new therapeutic scenario opened up by Gene Therapy (GT), it has become essential to identify and prioritize patient profiles for which GT could be applied. The "Pesaro Patients Risk Classification" showed the importance of risk stratification in order to achieve the best results. The Italian Scientific Society for Thalassemias and Hemoglobinopathies (SITE) closely involved in the cure and overall approach to these pathologies, decided to carry out this project of analysis and assessment to establish the possible inclusion and exclusion criteria for access to GT of patients with β-TDT and to collect the outcomes. The aim of this study is to identify wh...
Clinical Lymphoma Myeloma and Leukemia